This gut molecule shows remarkable anti-diabetes power: Study
Summary
Researchers discovered that the gut microbial metabolite TMA blocks the immune protein IRAK4, reducing inflammation and improving insulin sensitivity, offering potential new diabetes therapies.
Key Points
- Researchers identified the gut microbial metabolite trimethylamine (TMA) as a molecule that can block the immune protein IRAK4.
- TMA reduces inflammation caused by high-fat diets and improves insulin sensitivity, countering insulin resistance and type 2 diabetes.
- The molecule also protects mice from sepsis by weakening overwhelming inflammatory responses.
- IRAK4 is a known drug target, and inhibiting it shows promise as a new therapeutic strategy for diabetes treatment.
